2- Inhibition of the coronavirus uncoating
Chloroquine has shown in-vitro effects such as inhibition of uncoating
and glycosylation in various viruses, so it is an appropriate case study
for COVID-19 treatment according to accomplished clinical trials
conducted in China (5). In chloroquine administration, caution must be
taken since profound side effects such as retinopathy may proceed.
Chloroquine co-administration with lopinavir/ritonavir causes prolonged
QT interval, torsades de pointes, and may result in sudden death (30).
Pruritus is common. Rare adverse effects include hemolysis in glucose-
6-phosphate dehydrogenase (G6PD)-deficient persons, agranulocytosis,
hypotension, and electrocardiographic changes(28).